Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of malignant paraganglioma or pheochromocytoma and either evidence of metastases or unresectability. * Evidence of recent disease progression (radiological, biochemical, symptomatic). * Measurable disease defined as that which can be measured in at least one dimension with a minimum size of 10 mm by CT scan. * ECOG 0-2. * Life expectancy of greater than 24 weeks. * Age \> 18 years. * Patients must have normal organ and marrow function. * Patients must have PT/INR/PTT within 1.2 X the upper limit * Patients may have had prior radiation therapy. A minimum of 28 days must have elapsed between the end of radiotherapy and registration onto the study. * Previous Surgery: Previous major surgery is permitted provided that it has been at least 28 days prior to patient registration * Laboratory Requirements Parameter Limit granulocytes (AGC) \> 1.5 x 109/L platelets \> 100 x 109/L bilirubin \< 1.5XULN AST and ALT \< 2.5 x ULN Amylase \<1.5XULN Lipase \<1.5XULN Calcium \< 3 mmol/L creatinine \< 2.0XULN Exclusion Criteria: * History of other malignancies. * Patients with known brain metastases. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib. * Patients receiving concurrent treatment with other anti-cancer therapy given for paraganglioma or pheochromocytoma or other therapy or other investigational anticancer agents. * Patients who have received prior treatment with any other antiangiogenic agent or multi-targeted tyrosine kinase inhibitors are ineligible. * Patients with any of the following cardiovascular findings are to be excluded: * QTc prolongation or other significant ECG abnormalities. * Current or history of Class III or IV heart failure as defined by the NYHA functional classification system * Patients with prior anthracycline exposure, previous central thoracic radiation that included heart in radiation port, or a history of NYHA Class II cardiac function. * Poorly controlled hypertension * Myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry * History of venous thrombosis or pulmonary embolism in the past 3 months * History of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry * Patients who require use of therapeutic doses of coumarin-derivative anticoagulants such as warfarin * Patients with bowel obstruction or any condition that impairs their ability to swallow and retain sunitinib tablets. * Use of agents with proarrhythmic potential is not permitted during the study. * Must be able to stop prohibited selected CYP3A4 inhibitors/inducers prior to starting sunitinib * Patients with pre-existing hypothyroidism prior to enrolment are ineligible unless they are euthyroid on medication. * Pregnant or lactating women, positive pregnancy test, women of childbearing potential who do not agree to use adequate contraception prior to study entry and for the duration of study participation. * Known HIV-positive patients on combination antiretroviral therapy * Greater than +1 proteinuria on urinary dipstick if also \>1g urinary protein/24hrs